Key result
Cardiac troponins have emerged as potential biomarkers that may play a role in improving the risk stratification of patients with heart failure.
Why the study?
What is the utility of cardiac troponins in improving risk stratification for patients with heart failure?
What is the utility of cardiac troponins in improving risk stratification for patients with heart failure?
This review highlights the emerging role of cardiac troponins as prognostic biomarkers for risk stratification in heart failure.
Answers are grounded in this paper and cite their sources.
May support troponin use in HF risk models; leaves open prospective validation before practice change.
Many individual variables are predictive of an increased risk of mortality and morbidity in heart failure. These include a range of data from patient demographics, clinical findings, comorbidities and invasive and noninvasive parameters. Some of these markers, for example the B-type natriuretic peptides, have been identified as independently predictive in large, robust, multivariable analyses. However, many markers have had less vigorous scrutiny and were identified in small cohorts after only univariate or limited multivariable analyses. Recently, cardiac troponins have emerged as potential biomarkers for patients with heart failure. In this article, we consider the utility of cardiac troponins in heart failure and propose what role they may play in improving the risk stratification of this disease.
No takes yet. Share an insight, caveat, or question.
Jackson et al. (2009) conducted a review in Heart failure. Cardiac troponins was evaluated. Cardiac troponins have emerged as potential biomarkers that may play a role in improving the risk stratification of patients with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: